ABCC5 and benign prostatic hyperplasia: To study the correlations between ABCC5 and clinical enzalutamide-resistant CRPC progression at the protein level, we performed IHC staining on 80 samples (Supplementary Table 1), including 17 patients with BPH, 57 patients with primary PCa, and 6 patients with CRPC, and evaluated the correlation among ABCC5 expression, DFS and OS statistics from TCGA.